ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

S Korean pharma laid low by global retreat and Samsung scandal

Scandal compounds grim mood as international partnerships flop

Samsung Bioepis had high hopes for a diabetes biosimilar project with Merck, until the U.S. side canceled the deal. 

SEOUL -- South Korea's pharmaceutical companies are being frozen out of partnerships by major European and U.S. partners, hitting an industry already rocked by the Samsung BioLogics accounting scandal.

The country's drugmakers have faced a string of failed product development attempts. This has lessened their attraction for global pharma companies who are increasingly looking to startups or universities for partnerships. Failures are par for the course in a business where the success rate is estimated at 1 in 30,000, yet South Korean players' shares are falling across the board. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more